Ki-67 expression affects the clinical therapeutic effect on advanced lung adenocarcinoma
10.16571/j.cnki.1008-8199.2018.12.011
- VernacularTitle: 晚期肺腺癌患者Ki-67表达水平与临床疗效的关系
- Author:
Huan-wen XIONG
1
;
Guo-ji XIA
1
;
Guan-nan WU
2
Author Information
1. Department of Respiratory Medicine, the 94th Hospital of Chinese PLA, Nanchang 330002, Jiangxi, China
2. Department of Respiratory and Critical Care Medicine, Nanjing General Hospital of Nanjing Military Region, PLA, Nanjing 210002, Jiangsu, China
- Publication Type:Journal Article
- Keywords:
lung adenocarcinoma;
Ki-67;
first-line therapy;
curative effect
- From:
Journal of Medical Postgraduates
2018;31(12):1281-1284
- CountryChina
- Language:Chinese
-
Abstract:
Objective The expression level of the Ki-67 protein is a marker of the poor prognosis in non-small-cell lung cancer. This study explored the correlation of the Ki-67 expression level with the clinical efficacy in the treatment of advanced lung adenocarcinoma.Methods From January 2015 to December 2015, 92 patients with stage Ⅳ lung adenocarcinoma were treated in the Department of Respiratory and Critical Care Medicine of Nanjing General Hospital, 65 with oral gefitinib for EGFR mutation-positive or crizotinib for ALK positive (the targeted therapy \[TT\] group) and the other 27 with pemetrexed + cisplatin or nedaplatin (the chemotherapy \[CT\] group). The expression of Ki-67 was determined by immunohistochemistry, its relationship with the clinicopathological features and therapeutic effects was analyzed, and the progression-free survival (PFS) was calculated.Results Ki-67 was expressed lowly in 43 (46.7%) and highly in 49 (53.3%) of the cases. The median PFS after treatment was significantly longer in the patients with a low than in those with a high Ki-67 expression in the TT group (10 vs 7 mo, P<0.05) and in the CT group as well (8 vs 7 mo, P<0.05). Ki-67 (HR=1.011, 95% CI: 1.000-1.023) and ALK (HR=0.325, 95% CI: 0.112-0.942) were shown to be predictive factors of poor PFS.Conclusion The expression level of Ki-67 affects the effect of clinical treatment, especially that of the first-line targeted therapy, on advanced lung adenocarcinoma.
